Putting on Weight After Mounjaro: the Evidence and What It Means for You

What the SURMOUNT data actually say about weight after stopping

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults and showed average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks. A subsequent extension phase (where participants switched to placebo after completing tirzepatide) showed meaningful weight regain beginning within weeks of the last injection. By around a year post-treatment, much of the lost weight had returned in those who received no continued intervention.

This pattern is not unique to tirzepatide. Similar follow-up data from semaglutide trials show the same trajectory. The mechanism is well understood: Mounjaro works by stimulating GIP and GLP-1 receptors, which reduces appetite, slows gastric emptying and influences how the brain registers fullness. When that stimulation stops, the body's hunger signals reassert themselves. Putting weight on after Mounjaro, then, is largely a pharmacological rebound rather than any change in your habits.

For a broader look at how tirzepatide produces its effects and what the trial programme found, the tirzepatide overview on this site covers the mechanism in more detail. If your weight was already climbing before your final dose, the pattern seen in trials may well reflect what you are experiencing now.

Why some people regain faster than others

Not everyone puts weight back on at the same rate, and the NHS patient information for tirzepatide notes that individual response varies significantly. Several factors shape how quickly regain happens after stopping.

Starting dose and final dose both matter: people who reached higher maintenance doses and held them longest appear to have more physiological adaptation to reverse when stopping. How quickly the medicine is withdrawn also plays a role, a sudden stop removes all receptor stimulation at once, whereas a gradual taper (if clinically suitable) can soften the rebound in appetite.

Lifestyle factors built during treatment have a protective effect, but only up to a point. Dietary patterns, exercise habits and sleep all influence the rate of regain, though none fully replaces the pharmacological effect. The weight gain after Mounjaro page explores these contributing factors in more detail.

If you are putting weight on after Mounjaro and are not sure whether it is consistent with expected rebound or something else, it is worth reading about weight gain while still taking Mounjaro too, since the causes differ and the clinical responses differ accordingly.

The clinical options when weight starts to return

Regain after stopping is not a closed door. Clinically, several paths exist, and the right one depends on your current health status, BMI, any weight-related conditions, and your prescriber's judgement.

Restarting tirzepatide is the most direct option if you remain clinically eligible. The Mounjaro treatment page outlines the licensed eligibility criteria: adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as hypertension, dyslipidaemia or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Restarting generally means going back through the titration schedule; your prescriber will confirm the appropriate starting point based on how long you have been off treatment.

A planned maintenance approach (keeping the medicine at the lowest effective dose rather than stopping outright) is another option some clinicians discuss, though it requires continued prescribing and clinical review. There is also the question of cost: the Eli Lilly UK price increase from September 2025 is relevant context for anyone weighing up long-term private treatment.

Whatever direction you are considering, the evidence supports one conclusion: putting weight back on after Mounjaro is an expected pharmacological outcome, and it responds to pharmacological and clinical management. It is a clinical conversation, not a reason to give up.

What you can do right now, practically

If your last pen ran out a few weeks ago and you are already noticing your appetite climbing (the way it creeps back before breakfast feels different, or portions that felt fine during treatment now feel too small) that is the rebound the trials describe. It tends to happen faster than people expect.

A few things are worth doing now. First, check whether you still meet eligibility criteria by using the guide to Mounjaro weight thresholds, which covers how BMI and comorbidities interact under the licensed criteria. Second, speak to a prescriber: a clinical review can establish whether restarting, transitioning to another licensed treatment, or a structured behavioural plan is the most appropriate next step. The evidence on long-term weight outcomes after Mounjaro may also help frame what to expect over a longer horizon.

If you stopped treatment because of side effects, cost, or supply issues rather than reaching your goal, those circumstances are worth discussing openly in a consultation. You can also read about whether weight regain after Mounjaro is inevitable or whether the trajectory can be altered with the right support. Our prescribers at our clinical team review every consultation personally. If you would like to discuss your situation, check your eligibility to start a free consultation.